

Asa Henin

Partner



ahenin@cooley.com

Capital Markets

+1 858 550 6104

San Diego

Asa's practice focuses on representing publicly traded life sciences companies as primary outside corporate and securities counsel. He advises management and boards of directors on US Securities and Exchange Commission (SEC) reporting and disclosure requirements, proxy statements and shareholder meetings, stock exchange requirements, corporate governance, investor communications, and other corporate and securities matters. Asa also advises companies in connection with their pre-initial public offering (IPO) crossover financings, IPOs, follow-on public offerings, and private investment in public equity (PIPE) financings. He is a member of Cooley's corporate governance and securities regulation practice.

Asa's representative transactions include:

- Allogene Therapeutics – \$372.6 million IPO
- Kronos Bio – \$287.5 million IPO
- Longboard Pharmaceuticals – \$84.8 million IPO
- Travele Therapeutics – \$230.0 million follow-on equity offering
- Longboard Pharmaceuticals – \$241.5 million follow-on equity offering
- Regulus Therapeutics – \$100.0 million PIPE financing
- Tandem Diabetes Care – \$316.0 million Rule 144A convertible note offering
- Allogene Therapeutics – \$110.0 million underwritten nonpublic offering
- UroGen Pharma – \$116.2 million follow-on equity offering

Education

University of San Diego School of Law JD, magna cum laude, 2010

University of California, Santa Barbara BA, 2006

Admissions & Credentials

California

Rankings & Accolades

CALI Awards in Corporations and Securities Regulation, Recipient

Memberships & Affiliations

The State Bar of California